Apomorphine in Dopaminergic Therapy
The DOI matches its Crossref record.
Abstract
Apomorphine is a potent molecule for the treatment of Parkinson's disease (PD). It can be obtained in both the R and S forms, and it is the former that is the therapeutically active form. Due to its structural similarity with 3,4-dihydroxyphenethylamine, dopamine, apomorphine can function as an agonist in the treatment of PD as it can stimulate both the D1 and D2 receptors of the striatum. The clinical efficacy of apomorphine is similar to that of 3,4-dihydroxyphenylalanine, levodopa (L-dopa), the cornerstone drug in dopaminergic therapy. (R)-Apomorphine is efficacious for one of the most challenging aspects in the management of PD, namely, managing the unpredictable "on-off" period as a rescue medication after oral administration of a therapeutic drug such as L-dopa. The effectiveness is due to its rapid control of the wearing-off period of the orally administered medicine. This short review will trace the progress of apomorphine use starting with its initial discovery and the first indications for which it was used, discovery of its "cure" for PD, and the studies that led to demonstrating its therapeutic efficacy. The key structural features of apomorphine responsible for its activity are illustrated along with major issues of chemical stability. From a drug delivery point of view, the current form of administration of apomorphine and some of the potential alternate methods of delivery are reviewed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Intranasal delivery: Physicochemical and therapeutic aspects
Costantino, H. R., Illum, L., Brandt, G., Johnson, P. H., & Quay, S. C. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.03.025 · Cited by 598
Baell, J. B. (2016) · Journal of Natural Products · doi:10.1021/acs.jnatprod.5b00947 · Cited by 539
Nanostructured Lipid Carriers for Delivery of Chemotherapeutics: A Review
Haider, M., Abdin, S. M., Kamal, L., & Orive, G. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12030288 · Cited by 451
Nanostructured Lipid Carriers (NLCs) for Drug Delivery and Targeting
Fang, C.-L., A. Al-Suwayeh, S., & Fang, J.-Y. (2013) · Recent Patents on Nanotechnology · doi:10.2174/187221013804484827 · Cited by 367
Lin, C.-H., Chen, C.-H., Lin, Z.-C., & Fang, J.-Y. (2017) · Journal of Food and Drug Analysis · doi:10.1016/j.jfda.2017.02.001 · Cited by 298
Metadata
- Authors
- Subramony, J. A.
- Venue
- Molecular Pharmaceutics
- Publisher
- American Chemical Society (ACS)
- Published
- 2006-06-13
- Volume
- 3
- Issue
- 4
- Pages
- 380-385
- ISSN
- 1543-8384 (ISSN-L)
- 1543-8392
- OpenAlex
- W1977149635
- Cited by
- 65
- References
- 0
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Apomorphine in Dopaminergic Therapy. https://app.cochat.ai/papers/10.1021/mp060012c
- The paper
- Subramony, J. A. (2006). Apomorphine in Dopaminergic Therapy. Molecular Pharmaceutics. https://doi.org/10.1021/mp060012c
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.